Tag: Bioxyne Limited
Bioxyne signs $5.6M supply agreement to enter German medical cannabis market
Bioxyne Limited), through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
Bioxyne granted Australia’s first GMP licence for Psilocybin and MDMA manufacturing
Bioxyne Limited's subsidiary, Breathe Life Sciences (BLS), has secured the Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
